Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib for Imatinib/Sunitinib-failed GIST

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 years~* advanced GIST~* failed (progressed and/or intolerable) after prior treatments for GIST~* ECOG performance status of 0\~2~* resolution of all toxic effects of prior treatments~* no prior radiotherapy within 1 month before registration~* measurable lesion as defined by RECIST~* adequate marrow, hepatic, renal and cardiac functions~* provision of a signed written informed consent~Exclusion Criteria:~* severe co-morbid illness and/or active infections~* pregnant or lactating women~* history of other malignancies~* active CNS disease not controllable with radiotherapy or corticosteroids~* active and uncontrollable bleeding from gastrointestinal tract~* prior history of sorafenib use~* gastrointestinal obstruction or malabsorption syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Type: EXPERIMENTAL): The patients will receive daily oral administration of sorafenib 400 mg twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).